November 13, 2025
Ad Scientiam x Merck KGaA: innovating for myasthenia
Ad Scientiam and Merck KGaA announce a new collaboration to improve care for people living with autoimmune myasthenia.
This collaboration will lead to a prospective, multicenter pilot study, planned from 2026 in several European countries.
The objective: evaluate an investigational medical device software, combining a mobile application, a wearable activity sensor and electronic questionnaires, to collect digital measurements in real-life conditions, without supervision.
This solution aims to support patients and healthcare professionals in monitoring symptoms and evaluating disease impact.